Erlotinib Hydrochloride is a type of cancer medicine used to treat certain lung cancers. It works by blocking a protein that helps cancer cells grow. It's sometimes called Tarceva.
Every report comes from a Lived member, sent anonymously.
Have you tried Erlotinib for Non-Small Cell Lung Cancer?
Erlotinib is a targeted cancer medicine taken as a daily tablet. It was originally sold under the brand name Tarceva, which is no longer marketed in the US; generic erlotinib tablets are available. Its main use is non-small cell lung cancer (NSCLC), the most common type of lung cancer, once the cancer has spread to other parts of the body. Erlotinib is used only when testing of a tumor or blood sample finds one of two specific changes in a gene called EGFR (epidermal growth factor receptor): an exon 19 deletion or the L858R mutation. It can be the first treatment, a maintenance treatment that continues after initial therapy, or a later treatment after chemotherapy has stopped working. It has not been shown to work for other EGFR changes, is no longer approved for lung cancers without these mutations, and is not recommended in combination with platinum-based chemotherapy. Erlotinib is also approved together with gemcitabine, an intravenous chemotherapy drug, as a first treatment for pancreatic cancer that cannot be removed with surgery or has spread. The benefit there is small: in the main trial, median survival was 6.5 months with the combination and 6.0 months with gemcitabine alone. For lung cancer, a newer medicine in the same family, osimertinib (Tagrisso), helped people live longer than erlotinib or gefitinib when used as the first treatment in a large trial. That comparison is worth discussing when choosing where erlotinib fits.
EGFR is a receptor on the surface of cells that, when switched on, signals the cell to grow and divide. In some lung cancers, a mutation in the EGFR gene keeps this signal switched on, and the cancer comes to depend on it. Erlotinib belongs to a group called tyrosine kinase inhibitors: it blocks the part of EGFR that relays the growth signal inside the cell. It binds more strongly to the mutated forms of EGFR than to the normal receptor, which is why testing for those mutations decides who is likely to benefit. Normal EGFR also helps maintain the skin, hair follicles, nails and the lining of the gut. Blocking it there explains the medicine's most familiar side effects, an acne-like rash and diarrhea. Erlotinib can shrink tumors and hold them in check, but it does not cure advanced cancer.
Erlotinib is a tablet taken once a day on an empty stomach, meaning at least one hour before or two hours after eating. The usual dose is 150 mg for lung cancer and 100 mg for pancreatic cancer, where it is taken alongside gemcitabine infusions given at the clinic. Tablets come in 25, 100 and 150 mg strengths, which lets the dose be adjusted. Treatment continues for as long as the cancer stays controlled and side effects are manageable. If side effects become hard to tolerate, the oncologist may pause erlotinib and restart at a lower dose, usually in 50 mg steps. People who keep smoking may be prescribed a higher dose because smoking lowers erlotinib levels, and the dose is brought back down as soon as they stop. Dose changes should come from the care team rather than being made at home.
Rash and diarrhea are the most common side effects, and both usually start within the first month. The rash often looks like acne on the face, scalp, chest and back, and it can be worse on sun-exposed skin. Alcohol-free moisturizers, sunscreen, protective clothing and limiting sun exposure help, and the care team can prescribe treatment for rash that persists. Dry or cracked skin, itching, inflammation around the nails, and hair and nail changes are also common. Diarrhea can usually be managed with loperamide (Imodium); call the care team if it is severe or does not settle, because dehydration can strain the kidneys. Tiredness, poor appetite, cough and shortness of breath were also frequent in trials, partly reflecting the cancer itself. Erlotinib can also affect the eyes, causing dryness, irritation, conjunctivitis or abnormal eyelash growth. Contact the care team promptly about eye pain, redness, blurred vision, light sensitivity or other changes in vision, because untreated inflammation can damage the clear front surface of the eye (the cornea). A few serious reactions are uncommon but important to recognize. Call the care team right away about new or worsening shortness of breath or cough without an obvious cause, especially with fever: about 1 in 100 people develop interstitial lung disease, an inflammation of the lungs that can be fatal, and erlotinib is paused while it is checked. Report yellow skin or eyes, or dark urine, promptly, since erlotinib can rarely cause serious liver damage. Seek immediate medical attention for severe blistering or peeling skin, or for severe abdominal pain, which can signal a tear in the stomach or bowel wall (gastrointestinal perforation).
Several everyday factors change how much erlotinib reaches the bloodstream. Smoking lowers erlotinib levels, so stopping is advised, and the care team should hear about any change in smoking. Heartburn medicines reduce absorption too. Proton pump inhibitors such as omeprazole (Prilosec) are best avoided. H2 blockers such as famotidine (Pepcid) need careful timing, with erlotinib taken 10 hours after the H2 blocker and at least 2 hours before its next dose. Antacids should be taken several hours apart from erlotinib. Some medicines raise erlotinib to levels that cause more side effects, including certain antifungal medicines (such as itraconazole), the antibiotics clarithromycin and ciprofloxacin, some HIV medicines, and grapefruit or grapefruit juice. Others lower it, including the seizure medicines carbamazepine and phenytoin, the tuberculosis antibiotic rifampin and the herbal supplement St. John's wort. Check with the pharmacist before starting any new prescription, over-the-counter medicine or supplement. In people taking warfarin, a blood thinner, erlotinib can push up the INR (international normalized ratio, a blood test of how long blood takes to clot) and has caused serious and sometimes fatal bleeding, so INR is checked regularly. Steroids, anti-inflammatory pain relievers such as ibuprofen, some other cancer drugs, and a history of stomach ulcers or diverticular disease raise the risk of a bowel perforation. People with existing liver problems need closer monitoring because their risk of liver damage is higher. In pancreatic cancer treated with gemcitabine, adding erlotinib was linked to more strokes and to a rare disorder in which red blood cells and platelets are destroyed. Erlotinib can harm a developing baby. Use effective contraception during treatment and for one month after the last dose, and tell the care team right away about a known or suspected pregnancy. Do not breastfeed during treatment or for two weeks after the last dose.
Erlotinib is an ongoing daily treatment rather than a fixed course. Regular scans show whether the cancer is shrinking, stable or growing, and blood tests check liver and kidney function and salt levels in the blood. For people with qualifying EGFR mutations, tumors often shrink. In the main first-line lung cancer trial, tumors shrank in about two thirds of people taking erlotinib, compared with about one in six on chemotherapy, and the median time before the cancer grew again was about 10 months versus 5 months. Over time, the cancer grew again in most people, and the oncologist then looks at what comes next. Side effects tend to be most noticeable in the first weeks. In the same trial, about a third of people needed a pause or a lower dose because of side effects, and about 1 in 7 stopped erlotinib for that reason. A dose reduction does not mean the treatment has failed. Treating the rash and diarrhea early and keeping the care team informed are central to staying on treatment comfortably.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Erlotinib, what you've noticed, or ask the community a question.